Delving into the Latest Updates on Garenoxacin Mesilate Hydrate with Synapse

本研究以深圳万乐药业有限公司（生产单位：Toyama Plant，FUJIFILM Toyama Chemical Co.，Ltd.）提供的甲磺酸加诺沙星片（规格：200mg片形：圆形片）为受试制剂，以深圳万乐药业有限公司（生产单位： Toyama Plant，FUJIFILM Toyama Chemical Co.，Ltd.）提供的甲磺酸加诺沙星片（规格：200mg片形：八角形片）为参比制剂，评估受试制剂和参比制剂在空腹和餐后条件下的生物等效性。

[Translation]

In this study, ganofloxacin mesylate tablets (specification: 200 mg, tablet shape: round tablets) provided by Shenzhen Wanle Pharmaceutical Co., Ltd. (manufacturer: Toyama Plant, FUJIFILM Toyama Chemical Co., Ltd.) were used as the test preparation, and ganofloxacin mesylate tablets (specification: 200 mg, tablet shape: octagonal tablets) provided by Shenzhen Wanle Pharmaceutical Co., Ltd. (manufacturer: Toyama Plant, FUJIFILM Toyama Chemical Co., Ltd.) were used as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation under fasting and fed conditions.

Start Date07 Dec 2023

Sponsor / Collaborator

Beijing Yidu Zhengkang Health Technology Co., Ltd.

JPRN-UMIN000016373 / CompletedIIT

Clinical efficacy of garenoxacin for treatment of bacterial respiratory infection secondary to chronic respiratory disease - GARIREO study

Start Date30 Jan 2015

Sponsor / Collaborator-

JPRN-jRCT1080222731 / Unknown statusNot Applicable

Specific post-marketing surveillance of garenoxacin (Geninax) Clinical efficacy and safety of garenoxacin in the treatment of legionella pneumonia

Start Date29 Jan 2015

Sponsor / Collaborator

Toyama Chemical Co., Ltd.

100 Clinical Results associated with Garenoxacin Mesilate Hydrate

Login to view more data

100 Translational Medicine associated with Garenoxacin Mesilate Hydrate

Login to view more data

100 Patents (Medical) associated with Garenoxacin Mesilate Hydrate

Login to view more data

298

Literatures (Medical) associated with Garenoxacin Mesilate Hydrate

06 Aug 2024·Environmental Science & Technology

Solar Photodegradation of a Novel des-F(6)-Fluoroquinolone, Garenoxacin, and Ecotoxicity of Its Phototransformation Products

Article

Author: Huang, Shengnan ; Cheng, Hefa ; Zhang, Zhaobin ; Lin, Chunye

Garenoxacin (GRNX) is a novel des-F(6)-fluoroquinolone on the horizon; thus, its fate and risk in the aquatic environment deserve attention. This study systematically investigated, for the first time, the phototransformation of GRNX under simulated and natural sunlight and assessed the ecotoxicity of its photodegradation products. Phototransformation of GRNX was observed to depend strongly on its ionization state, with direct photolysis and self-sensitized photolysis having comparable contributions for the cationic and zwitterionic species, while the latter dominated for the anionic species. Singlet oxygen generated via the self-sensitized photolysis of GRNX was the major reactive oxygen species in its photodegradation. Phototransformation of GRNX in different ionization states followed distinct pathways, with defluorination of the difluoromethyl group occurring only for the zwitterionic and anionic species. GRNX photodegradation in natural water could be described by a simple kinetic model based on the measured steady-state concentrations of ¹O₂ and ·OH. Toxicity tests with Vibrio fischeri and Chlorella vulgaris consistently indicate that the generation of hydroxylation and decarboxylation products during photodegradation of GRNX increased the acute toxicity. These findings not only provide insights into the fate of GRNX in sunlit surface water but also reveal the potentially significant risk of its photodegradation products to the aquatic ecosystem.

01 Feb 2024·European Journal of Dermatology

Fixed drug eruption due to tipepidine hibenzate and garenoxacin mesylate hydrate: an unusual case of polysensitivity

Article

Author: Harada, Yuya ; Fukuda, Hidetsugu

10 Nov 2023·Cureus

Fixed Drug Eruption Caused by Garenoxacin: A Case Report and Literature Review

Author: Sawada, Yu ; Saito-Sasaki, Natsuko ; Hara, Natsumi

A new quinolone antibiotic called garenoxacin was developed in Japan. Garenoxacin is known to produce cutaneous adverse effects, particularly fixed drug eruption in Japan, despite several reports of cutaneous adverse events in English-language literature. However, English-language literature has not yet reported that fixed drug eruption is a common clinical manifestation of garenoxacin-induced drug eruption. In this article, we present a case of multiple fixed drug eruptions and review the literature on case reports of drug eruptions caused by garenoxacin.

100 Deals associated with Garenoxacin Mesilate Hydrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Garenoxacin Mesilate Hydrate	J01MA19	DB06160

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Escherichia Coli Infections	JP	Taisho Pharmaceutical Co., Ltd.	31 Jul 2023
Klebsiella Infections	JP	Astellas Pharma, Inc.	31 Jul 2023
Klebsiella Infections	JP	Taisho Pharmaceutical Co., Ltd.	31 Jul 2023
Mycoplasma Infections	JP	Astellas Pharma, Inc.	31 Jul 2023
Mycoplasma Infections	JP	Taisho Pharmaceutical Co., Ltd.	31 Jul 2023
Otitis Media	JP	Astellas Pharma, Inc.	31 Jul 2023
Otitis Media	JP	Taisho Pharmaceutical Co., Ltd.	31 Jul 2023
Pharyngolaryngitis	JP	Taisho Pharmaceutical Co., Ltd.	31 Jul 2023
Pharyngolaryngitis	JP	Astellas Pharma, Inc.	31 Jul 2023
Pneumococcal Infections	JP	Taisho Pharmaceutical Co., Ltd.	31 Jul 2023
Pneumococcal Infections	JP	Astellas Pharma, Inc.	31 Jul 2023
Pneumonia, Bacterial	CN	FUJIFILM Toyama Chemical Co., Ltd.	25 Jul 2019
Respiratory Tract Infections	CN	Toyama Chemical Co., Ltd.	12 Jul 2019
Bacterial Infections	KR	Dong-A ST Co., Ltd.	01 Sep 2009
Acute Bronchitis	JP	FUJIFILM Toyama Chemical Co., Ltd.	31 Jul 2007
Laryngitis	JP	FUJIFILM Toyama Chemical Co., Ltd.	31 Jul 2007
Pneumonia	JP	FUJIFILM Toyama Chemical Co., Ltd.	31 Jul 2007
respiratory tract; infection, chronic	JP	FUJIFILM Toyama Chemical Co., Ltd.	31 Jul 2007
Sinusitis	JP	FUJIFILM Toyama Chemical Co., Ltd.	31 Jul 2007
Tonsillitis	JP	FUJIFILM Toyama Chemical Co., Ltd.	31 Jul 2007

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bronchitis, Chronic	Preclinical	EU	Merck GmbH	-
Community Acquired Pneumonia	Preclinical	EU	Merck GmbH	-
Complicated skin and soft tissue infection	Preclinical	EU	Merck GmbH	-
Intraabdominal Infections	Preclinical	EU	Merck GmbH	-